Changes in Triglyceride and Other Lipids (Levels of Fats Found in Blood) When Taking Darunavir Compared to Atazanavir in HIV-infected Patients That Have Never Received Treatment
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00757783 |
|
Recruitment Status :
Completed
First Posted : September 23, 2008
Results First Posted : September 10, 2010
Last Update Posted : December 30, 2015
|
Sponsor:
Tibotec, Inc
Collaborator:
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA
Information provided by (Responsible Party):
Tibotec, Inc
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
The purpose of this research study is to compare changes in triglyceride and other lipids (levels of fats found in the blood) from Baseline (Day 1) to Week 12 for darunavir/ritonavir 800/100 mg once daily versus atazanavir/ritonavir 300/100 mg once daily in combination with a fixed-dose background regimen consisting of emtricitabine [FTC]/tenofovir [TDF] 200/300 mg once daily). This study will also evaluate the safety (adverse events), effectiveness, and tolerability of darunavir/ritonavir and atazanivir/ritonavir over 48 weeks.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| HIV | Drug: ritonavir Drug: darunavir Drug: emtricitabine [FTC]/tenofovir [TDF] Drug: atazanavir | Phase 4 |
The purpose of this study is to expand our understanding of the metabolic effects of darunavir/ritonavir (DRV/r) in HIV-infected patients. This is a phase 4, multicenter, open-label, randomized (study drug assigned by chance), comparative study designed to compare changes in lipid, glucose, and insulin parameters in HIV-infected, anti-retroviral (ARV) naive patients treated with DRV/r 800/100 mg once daily (QD) versus atazanavir/ritonavir (ATV/r) 300/100 mg QD in combination with a common background of emtricitabine (FTC)/ tenofovir (TDF) 200/300 mg QD. In addition, changes in inflammatory markers will be measured. A substudy of the parent study TMC114HIV4023 will evaluate insulin sensitivity and endothelial function in a subset of patients. The study will be conducted at approximately 16 study sites in the United States. Approximately 60 HIV-1 infected, treatment-naive adult patients will be enrolled in the study. Screening will take place during a 4-week period. At the baseline visit, eligible patients will be randomized in a 1:1 ratio to receive DRV/r 800/100 mg QD or ATV/r 300/100 mg QD administered in combination with a fixed-dose background regimen consisting of emtricitabine (FTC)/tenofovir (TDF) 200/300 mg once daily. The treatment period is 48 weeks. Study assessments will be performed at clinic visits at the end of weeks 4, 8, 12, 24, 36, and 48. The primary endpoint will be assessed at week 12. All patients will return for follow up visits 1 week and 4 weeks after the completion of study treatment. During the treatment period, the patient will be seen at regular visits during which the investigator will assess the patient's medical condition, any Adverse Events and study drug compliance. Laboratory evaluations for efficacy and safety will be done at regular visits as well as blood pressure monitoring. Up to twenty patients (evenly randomized to receive DRV/r or ATV/r) who meet additional entry criteria will be enrolled in the substudy. The study hypothesis is the change in triglycerides and other lipids from baseline to week 12 will be similar in the DRV/r arm versus the ATV/r arm. The substudy hypothesis is that DRV/r will not adversely affect insulin sensitivity or endothelial function during 12 weeks of therapy, and the change from baseline in insulin sensitivity and endothelial function will be similar in the DRV/r arm versus the ATV/r arm. During the treatment period, the patient will be seen at regular visits during which the investigator will assess the patient's medical condition, any Adverse Events and study drug compliance. Laboratory evaluations for efficacy and safety will be done at regular visits as well as blood pressure monitoring. Patients will be randomized in a 1:1 ratio to receive darunavir/ritonavir 800/100 mg once daily (QD) plus emtricitabine (FTC)/tenofovir (TDF) 200/300 mg QD or atazanavir/ritonavir 300/100 mg QD plus emtricitabine (FTC)/tenofovir (TDF) for 48 weeks.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 68 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Multicenter, Open-label, Randomized Study to Assess the Metabolics, Efficacy, and Safety of Once-daily Darunavir Versus Atazanavir in HIV-infected Treatment-naive Adult Patients |
| Study Start Date : | October 2008 |
| Actual Primary Completion Date : | August 2009 |
| Actual Study Completion Date : | July 2012 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: darunavir
darunavir 800 mg tablet once daily for 48 weeks,emtricitabine [FTC]/tenofovir [TDF] 200/300 mg tablet once daily for 48 weeks,ritonavir 100 mg capsule or tablet once daily for 48 weeks
|
Drug: ritonavir
100 mg capsule or tablet once daily for 48 weeks Drug: darunavir 800 mg tablet once daily for 48 weeks Drug: emtricitabine [FTC]/tenofovir [TDF] 200/300 mg tablet once daily for 48 weeks |
|
Experimental: atazanavir
atazanavir 300 mg capsule once daily for 48 weeks,emtricitabine [FTC]/tenofovir [TDF] 200/300 mg once daily for 48 weeks,ritonavir 100 mg capsule or tablet once daily for 48 weeks
|
Drug: ritonavir
100 mg capsule or tablet once daily for 48 weeks Drug: emtricitabine [FTC]/tenofovir [TDF] 200/300 mg once daily for 48 weeks Drug: atazanavir 300 mg capsule once daily for 48 weeks |
Primary Outcome Measures :
- Change From Baseline in Fasting Triglyceride (TG) Levels in the Lipid Evaluable (LE) Set at Week12 [ Time Frame: Baseline, Week 12 ]Observed values.
Secondary Outcome Measures :
- Change From Baseline in Total Cholesterol (TC) Levels in the LE Set at Week 12 and 48 [ Time Frame: Baseline, Week 12 and 48 ]Observed Values
- Change From Baseline in Low Density Lipoprotein (LDL) Direct in the LE Set at Week 12 and 48. [ Time Frame: Baseline, Week 12 and 48 ]Observed Values
- Change From Baseline in High Density Lipoprotein (HDL) in the LE Set at Week 12 and 48. [ Time Frame: Baseline, Week 12 and 48 ]Observed Values
- Change From Baseline in Apolipoprotein A1 in the LE Set at Week 12 and 48. [ Time Frame: Baseline, Week 12 and 48 ]Observed Values
- Change From Baseline in Apolipoprotein B in the LE Set at Week 12 and 48. [ Time Frame: Baseline, Week 12 and 48 ]Observed Values
- Change From Baseline in TC/HDL Ratio in the LE Set at Week 12 and 48. [ Time Frame: Baseline, Week 12 and 48 ]Participants TC and HDL was analyzed at Baseline and Week 12 and 48. Change from Baseline at Week 12 and 48 was calculated as ratio using observed values.
- Change From Baseline in Glucose at Week 12 and 48. [ Time Frame: Baseline, Week 12 and 48 ]Participants glucose level was analyzed at Baseline and Week 12 and 48. Change from Baseline at Week 12 and 48 was reported.
- Change From Baseline in Insulin at Week 12 and 48. [ Time Frame: Baseline, Week 12 and 48 ]Participants insulin was analyzed at Baseline and Week 12 and 48 and change from Baseline at Week 12 and 48 were reported.
- Change From Baseline in Homeostasis Model Assessment-Insulin Resistance (HOMA-IR) at Week 12 and 48. [ Time Frame: Baseline, Week 12 and 48 ]Participants homeostasis model assessment-insulin resistance (HOMA-IR) were observed and change from Baseline were reported. HOMA-IR score was calculated as: (fasting plasma glucose*fasting serum insulin)/22.5. Low HOMA IR values indicate high insulin sensitivity and high HOMA IR values indicate low insulin sensitivity (insulin resistance).
- Antiviral Activity, Human Immunodeficiency Virus Type 1 (HIV-1) RNA. [ Time Frame: Week 12 and 48 ]Number of Participants with antiviral activity, human immunodeficiency virus Type 1 (HIV-1) RNA less than (<) 50 copies per milliliters (copies/mL) or < 400 copies/mL.
- Number of Participants With Antiviral Activity, HIV-1 RNA, Missing Values as Treatment Failure (M=F) [ Time Frame: Week 12 and 48 ]Number of participants with antiviral activity, HIV-1 RNA, missing values as treatment failure (Missing = Failure) were observed.
- Change From Baseline in HIV-1 RNA Viral Load at Week 12 and 48. [ Time Frame: Baseline, Week 12 and 48 ]the HIV-1 RNA viral load was calculated using Log Base 10 transformed HIV-1 RNA observed values.
- Change From Baseline in CD4 Cell Count at Week 12 and 48, Observed Values. [ Time Frame: Baseline, Week 12 and 48 ]Participants' Cluster of Differentiation (CD) 4 Cell Count were at baseline and the change values at Week 12 and 48 were observed.
- Change From Baseline in Cluster of Differentiation (CD) 4 Cell Count at Week 12 and 48, Last Observation Carried Forward (LOCF). [ Time Frame: Baseline, Week 12 and 48 ]Participants' Cluster of Differentiation (CD) 4 Cell Count were observed at baseline and the change values at Week 12 and 48 was calculated using LOCF.
- Change From Baseline in Cluster of Differentiation (CD) 4 Percent at Week 12 and 48, Last Observation Carried Forward (LOCF). [ Time Frame: Baseline, Week 12 and 48 ]Participants' Cluster of Differentiation (CD) 4 percent were observed at baseline and the change values at Week 12 and 48 was calculated using LOCF.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 99 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- HIV-1 RNA of 1000 copies/mL or more
- No previous treatment with antiretroviral drugs for more than 10 days
- Demonstrated sensitivity [Fold Change (FC) = lower Clinical Cut Off (CCO)] to tenofovir, darunavir and atazanavir
- Demonstrated sensitivity to emtricitabine defined as absence of M184V/I mutation
- Any CD4 (Cluster of Differentiation 4) cell count
Exclusion Criteria:
- Body mass index >30 kg/m2
- Laboratory parameters as follows: fasting glucose >110 mg/dL, Low-Density Lipoprotein (LDL) cholesterol >130 mg/dL, triglycerides >200 mg/dL
- Presence of any currently active AIDS-defining illness
- Treatment for primary HIV infection or postexposure prophylaxis for HIV
- Patients with acute or chronic hepatitis A, B or C infection
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00757783
Locations
| United States, California | |
| Los Angeles, California, United States | |
| United States, Connecticut | |
| Glastonbury, Connecticut, United States | |
| United States, District of Columbia | |
| Washington, District of Columbia, United States | |
| United States, Florida | |
| Fort Lauderdale, Florida, United States | |
| Miami, Florida, United States | |
| Orlando, Florida, United States | |
| United States, Indiana | |
| Indianapolis, Indiana, United States | |
| United States, Massachusetts | |
| Boston, Massachusetts, United States | |
| United States, Minnesota | |
| Minneapolis, Minnesota, United States | |
| United States, Missouri | |
| Saint Louis, Missouri, United States | |
| United States, New Jersey | |
| Hillsborough, New Jersey, United States | |
| United States, New York | |
| New York, New York, United States | |
| United States, Ohio | |
| Cincinnati, Ohio, United States | |
| United States, Pennsylvania | |
| Philadelphia, Pennsylvania, United States | |
| United States, Texas | |
| Dallas, Texas, United States | |
Sponsors and Collaborators
Tibotec, Inc
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA
Investigators
| Study Director: | Tibotec, Inc. Clinical Trial | Tibotec, Inc |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Tibotec, Inc |
| ClinicalTrials.gov Identifier: | NCT00757783 History of Changes |
| Other Study ID Numbers: |
CR015439 TMC114HIV4023 ( Other Identifier: Tibotec, Inc. ) |
| First Posted: | September 23, 2008 Key Record Dates |
| Results First Posted: | September 10, 2010 |
| Last Update Posted: | December 30, 2015 |
| Last Verified: | November 2015 |
Keywords provided by Tibotec, Inc:
|
HIV AIDS Immunodeficiency Virus, Human PREZISTA darunavir TMC114 |
Protease Inhibitor Truvada Atazanavir REYATAZ HIV Infections Treatment Naïve |
Additional relevant MeSH terms:
|
Ritonavir Darunavir Atazanavir Sulfate Tenofovir Emtricitabine HIV Protease Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |
Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents Cytochrome P-450 CYP3A Inhibitors Cytochrome P-450 Enzyme Inhibitors Reverse Transcriptase Inhibitors Nucleic Acid Synthesis Inhibitors |